Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 2/20 | 0.44 |
| ▸ | RARG | P13631 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 8/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655055 | 0.90 | RXRA (0.41) | RARBRARGRXRARARAPTGS1 | |
| SCHEMBL5654519 | 0.90 | RXRA (0.43) | RARBRARGRXRARARAPTGS1 | |
| SCHEMBL5656531 | 0.90 | RXRA (0.39) | RARBRARGRXRAPTGS1PTGS2 | |
| SCHEMBL5664203 | 0.88 | RXRA (0.41) | RARBRARGRXRAPTGS1PTGS2 | |
| SCHEMBL5655013 | 0.88 | PTGS2 (0.42) | RXRAPTGS1PTGS2ALOX5 | |
| SCHEMBL5654905 | 0.88 | RXRA (0.39) | RARBRARGRXRAPTGS1PTGS2 | |
| SCHEMBL5658187 | 0.85 | ESRRA (0.50) | RXRA | |
| SCHEMBL5658183 | 0.85 | ESRRA (0.50) | RXRA | |
| SCHEMBL14572375 | 0.85 | ESRRA (0.50) | RXRA | |
| SCHEMBL5657029 | 0.83 | RXRA (0.39) | RXRAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196108-B2 | Bicyclic heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1487446-A4 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1487446-A2 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | Incyte San Diego, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040034004-A1 | Bicyclic heterocycles for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2003075858-A2 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034004-A1 | Bicyclic heterocycles for the treatment of diabetes and other diseases | PC, CYP27A1, GPR119 | RARB 3268/4885RARG 1834/4885RXRA 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.